For the year ending 2025-12-31, ABT had $906M increase in cash & cash equivalents over the period. $7,395M in free cash flow.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net earnings | 6,524 | 13,402 | 5,723 | 6,933 |
| Depreciation | 1,434 | 1,340 | 1,277 | 1,254 |
| Amortization of intangible assets | 1,682 | 1,878 | 1,966 | 2,013 |
| Share-based compensation | 664 | 673 | 644 | 685 |
| Investing and financing losses, net | -65 | -482 | -126 | -215 |
| Trade receivables | 652 | 691 | 356 | 68 |
| Inventories | -195 | 58 | 232 | 1,413 |
| Prepaid expenses and other assets | 1,295 | 796 | 542 | 75 |
| Trade accounts payable and other liabilities | 954 | 356 | -760 | 420 |
| Income taxes | -5 | -8,028 | -585 | -383 |
| Net cash from operating activities | 9,566 | 8,558 | 7,261 | 9,581 |
| Acquisitions of property and equipment | 2,171 | 2,207 | 2,202 | 1,777 |
| Acquisitions of businesses and technologies, net of cash acquired | 105 | 0 | 877 | 0 |
| Proceeds from business dispositions | 0 | 1 | 40 | 48 |
| Purchases of investment securities | 167 | 169 | 159 | 185 |
| Proceeds from sales of investment securities | 3 | 28 | 43 | 152 |
| Other | -18 | -9 | -22 | -22 |
| Net cash from (used in) investing activities | -2,422 | -2,338 | -3,133 | -1,740 |
| Proceeds from issuance of (repayments of) short-term debt, net and other | -115 | -100 | 21 | 47 |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 5 | 223 | 2 | 7 |
| Repayments of long-term debt and debt with maturities over 3 months | 1,504 | 660 | 2,498 | 753 |
| Purchases of common shares | 893 | 1,295 | 1,227 | 3,795 |
| Proceeds from stock options exercised | 396 | 264 | 167 | 167 |
| Dividends paid | 4,116 | 3,836 | 3,556 | 3,309 |
| Other | -82 | - | - | 0 |
| Net cash from (used in) financing activities | -6,309 | -5,404 | -7,091 | -7,636 |
| Effect of exchange rate changes on cash and cash equivalents | 71 | -96 | -23 | -122 |
| Net increase (decrease) in cash and cash equivalents | 906 | 720 | -2,986 | 83 |
| Cash and cash equivalents, beginning of year | 7,616 | 6,896 | 9,882 | 9,799 |
| Cash and cash equivalents, end of year | 8,522 | 7,616 | 6,896 | 9,882 |
ABBOTT LABORATORIES (ABT)
ABBOTT LABORATORIES (ABT)